Adelaide Research & Scholarship: Search

Search

Results 21-30 of 39 (Search time: 0.002 seconds).

previous
1
2
3
4
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2013	Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial	Vermorken, J.; Stohlmacher-Williams, J.; Davidenko, I.; Licitra, L.; Winquist, E.; Villanueva, C.; Foa, P.; Rottey, S.; SkladowskI, K.; Tahara, M.; Pai, V.; Faivre, S.; Blajman, C.; Forastiere, A.; Stein, B.; Oliner, K.; Pan, Z.; Bach, B.
	2015	Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years	Wabe, N.; Sorich, M.; Wechalekar, M.; Cleland, L.; McWilliams, L.; Lee, A.; Spargo, L.; Metcalf, R.; Hall, C.; Proudman, S.; Wiese, M.
	2011	Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial	Kantarjian, H.; Hochhaus, A.; Saglio, G.; de Souza, C.; Flinn, I.; Stenke, L.; Goh, Y.; Rosti, G.; Nakamae, H.; Gallagher, N.; Hoenekopp, A.; Blakesley, R.; Larson, R.; Hughes, T.
	2010	Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)	Hughes, T.; Hochhaus, A.; Branford, S.; Muller, M.; Kaeda, J.; Foroni, L.; Druker, B.; Guilhot, F.; Larson, R.; O'Brien, S.; Rudoltz, M.; Mone, M.; Wehrle, E.; Modur, V.; Goldman, J.; Radich, J.
	2012	Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: Preclinical evaluation and results of the Phase II DUX Study in chemotherapy-refractory, advanced colorectal cancer	Weickhardt, A.; Price, T.; Chong, G.; Gebski, V.; Pavlakis, N.; Johns, T.; Azad, A.; Skrinos, E.; Fluck, K.; Dobrovic, A.; Salemi, R.; Scott, A.; Mariadason, J.; Tebbutt, N.
	2011	Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results	Kantarjian, H.; Giles, F.; Bhalla, K.; Pinilla-Ibarz, J.; Larson, R.; Gattermann, N.; Ottmann, O.; Hochhaus, A.; Radich, J.; Saglio, G.; Hughes, T.; Martinelli, G.; Kim, D.; Shou, Y.; Gallagher, N.; Blakesley, R.; Baccarani, M.; Cortes, J.; le Coutre, P.
	2011	Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells	Tang, M.; Gonen, M.; Quintas-Cardama, A.; Cortes, J.; Kantarjian, H.; Field, C.; Hughes, T.; Branford, S.; Michor, F.
	2011	Diagnostic accuracy of adenosine stress cardiovascular magnetic resonance following acute ST-segment elevation myocardial infarction post primary angioplasty	Wong, T.; Leung, M.; Das, R.; Liew, G.; Williams, K.; Dundon, B.; Molaee, P.; Teo, K.; Meredith, I.; Worthley, M.; Worthley, S.
	2010	Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with Imatinib	White, D.; Dang, P.; Engler, J.; Frede, A.; Osborn, M.; Saunders, V.; Manley, P.; Zrim, S.; Hughes, T.
	2016	Human milk intake in preterm infants and neurodevelopment at 18 months corrected age	Jacobi-Polishook, T.; Collins, C.; Sullivan, T.; Simmer, K.; Gillman, M.; Gibson, R.; Makrides, M.; Belfort, M.